Kadmos Capital is a UK-based venture capital fund focused on early-stage deep-tech companies with positive impact across artificial intelligence, sustainability and longevity.
Remy serves as Managing Partner at Kadmos Capital. He previously held investment and advisory roles at Deep Science Ventures, Calibrate Management, and Morgan Stanley.
The financing round was led by Soulmates Ventures with backing from several new and existing investors.
"Antiverse is tackling one of the most technically demanding problems in drug discovery. The team’s ability to reduce the development time for de novo therapeutic-grade antibodies in a defined domain to under four months is a significant scientific and operational achievement. This capability, combined with the AI-driven design and in-house labs, positions Antiverse on track to become a global leader and the go-to developer of antibody therapies for the most elusive disease targets in medicine"
The oversubscribed financing was led by Ahren Innovation Capital and will support preclinical validation and platform development.
"Partnering with the team at o2h discovery is a fantastic milestone for OutSee as we look ahead to commencing our first drug discovery programme and showcasing the potential of our Nomaly platform to revolutionise target discovery. The agreement is testament to the strength of our technology and, in combination with the closure of our oversubscribed seed funding round, kicks off a very exciting year. Thank you to our investors and supporters for their continued support, and the hard work and dedication of our team."
The funding round will support the development of hospital-ready diagnostic products and broaden clinical access to glycan testing.
"Together with genetics, the concept of personalised medicine requires a dynamic approach. Genomics provides the blueprint of where we begin, but health is not static—it evolves with time, environment, and lifestyle. To truly transform care, we must complement genomic insights with modifiable biomarkers: biological signals that capture real-time responses to interventions and track improvement longitudinally. This synergy between genomics and adaptive biomarkers is the cornerstone for turning personalised medicine from a descriptive concept into actionable, measurable, and preventative healthcare."
The funding was co-led by Kadmos Capital and Clay Capital to expand the company's enzyme engine and wet-lab capabilities.
"Scindo represents exactly the type of company we seek to back – one that combines data-driven approaches with strong technical talent to address sustainability challenges,"
The financing round was led by Ahren Innovation Capital and will support the expansion of the company's in-house target discovery programme.
"OutSee’s Nomaly technology is a truly next-generation genomic analysis tool with potential to transform drug discovery using powerful data-driven insights. It allows us to interrogate smaller datasets, and even data that has already been analysed, to uncover unique target insights that until now would have remained undetected."
.png)
